GMP IPO Watch
Bandhan Healthcare Fund
Direct Plan · Growth · Bandhan Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.48% | +3.52% | 170 of 255 |
| 1M | +1.54% | +1.97% | 156 of 255 |
| 3M | -0.14% | -3.45% | 38 of 252 |
| 6M | +12.60% | +2.92% | 31 of 251 |
| YTD | +14.71% | +1.21% | 27 of 255 |
| INCEPTION | +14.07% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.98% | +19.51% | -7.57% | 70% | 29% |
| 6M | +14.69% | +26.09% | +1.57% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity93.55%
- Debt0.00%
- Cash6.45%
- Other0.00%
Market Cap Split
- Large Cap29.17%
- Mid Cap31.29%
- Small Cap33.09%
- Others6.45%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.89 | 41.94 |
| P/B | 5.37 | 6.29 |
| Price / Sales | 5.27 | 6.05 |
| Price / Cash Flow | 28.26 | 31.26 |
| Dividend Yield (%) | 0.78 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 9.74% | -0.74% |
| Triparty Repo TRP_011026 | Reverse Repo / TREPS | 6.72% | — |
| Cipla | Pharmaceuticals & Biotechnology | 6.18% | -0.20% |
| Apollo Hospitals | Equity | 5.75% | +0.11% |
| Max Healthcare Institute | Equity | 5.27% | -0.54% |
| Lupin | Pharmaceuticals & Biotechnology | 4.35% | +0.39% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 4.27% | -0.01% |
| Shilpa Medicare | Pharmaceuticals & Biotechnology | 4.17% | +0.45% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.10% | -0.04% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 3.78% | +0.30% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.39% | -0.29% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.23% | -0.13% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 3.11% | +0.06% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.82% | +0.04% |
| Narayana Hrudayalaya | Equity | 2.74% | +0.15% |
View all 38 holdings
| Syngene International | Equity | 2.46% | +0.04% |
| Rainbow Childrens Medicare | Equity | 2.21% | +0.08% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 2.19% | -0.16% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.14% | -0.10% |
| Global Health | Equity | 1.88% | -0.57% |
| Novartis | Pharmaceuticals & Biotechnology | 1.88% | +0.38% |
| Pfizer | Pharmaceuticals & Biotechnology | 1.54% | -0.30% |
| Sanofi | Pharmaceuticals & Biotechnology | 1.50% | -0.01% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 1.48% | -0.01% |
| Healthcare Global Enterprises | Equity | 1.33% | -0.33% |
| Thyrocare Technologies | Equity | 1.31% | -0.15% |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 1.26% | -0.20% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.22% | -0.52% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 1.17% | +0.07% |
| Sai Parenteral's | Pharmaceuticals & Biotechnology | 1.15% | +0.20% |
| Alivus Life Sciences | Pharmaceuticals & Biotechnology | 1.15% | -0.21% |
| AstraZeneca Pharma | Pharmaceuticals & Biotechnology | 1.14% | -0.12% |
| Orchid Pharma | Pharmaceuticals & Biotechnology | 1.13% | +0.05% |
| Dr. Lal Path Labs | Equity | 0.91% | +0.03% |
| Medi Assist Healthcare | Insurance | 0.83% | -0.06% |
| Viyash Scientific | Pharmaceuticals & Biotechnology | 0.77% | -0.08% |
| Cash Margin - CCIL | Net Current Assets | 0.04% | — |
| Net Current Assets | Net Current Assets | -0.31% | — |
Sector Allocation · Sep 2026
Risk Metrics
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 3Y | 0.59 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Bandhan AMC Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
BANDHAN INNOVATION FUND
Direct Plan · Growth
|
+14.35% | — | — | +20.03% |
|
Bandhan BSE Healthcare Index Fund
Direct Plan · Growth
|
+14.13% | — | — | +8.12% |
|
Bandhan US Treasury Bond 0-1 year specific Debt Passive FOF
Direct Plan · IDCW
|
+10.64% | +8.91% | — | +8.51% |
|
Bandhan Gilt Fund
Direct Plan · Growth
|
+7.31% | +8.25% | +6.45% | +8.58% |
|
Bandhan CRISIL-IBX Financial Services 3-6 Months Debt Index Fund
Direct Plan · Growth
|
+6.77% | — | — | +7.03% |
|
BANDHAN Dynamic Term Fund
Direct Plan · Growth
|
+6.71% | +7.89% | +6.20% | +8.15% |
|
Bandhan Money Market Fund
Direct Plan · Periodic IDCW
|
+6.56% | +7.39% | +6.77% | +4.70% |
|
BANDHAN LIQUID Fund
Direct Plan · Periodic IDCW
|
+6.46% | +6.88% | +6.41% | +1.51% |
|
BANDHAN Arbitrage Fund
Direct Plan · Growth
|
+6.43% | +7.26% | +6.79% | +6.91% |
|
BANDHAN ULTRA SHORT TERM FUND
Direct Plan · Periodic IDCW
|
+6.43% | +7.19% | +6.61% | +4.33% |
About This Scheme
Investment Objective
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors. Disclaimer: There is no assurance or guarantee that the scheme’s objectives will be realised.
Stated Asset Allocation
Equity & equity related instruments engaged in Healthcare, Pharma and Allied sectors - 80%-100%, Equity & Equity related securities other than above and overseas securities - 0% - 20% Debt Securities and Money Market Instruments (including Government securities, Securitised debt) - 0% - 20% Units issued by InvITs - 0% - 10%
Exit Load
• If redeemed/switched out on or within 30 days from the date of allotment: 0.50% of the applicable NAV • If redeemed/switched out after 30 days from date of allotment – Nil
Fund Managers
Mr. Viraj Kulkarni, Mr. Brijesh Shah, Ms. Ritika Behera and Mr. Gaurav Satra
Comanage - Mr. Viraj Kulkarni (equity portion), Mr. Brijesh Shah (Debt portion), Ms. Ritika Behera (overseas portion) and Mr. Gaurav Satra (overseas portion)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.